By Editor , 3 September 2026
Jazz's Ziihera Shows Significant Survival Edge Over Trastuzumab in GEA Trial

Dublin – September 03, 2026 -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) reported that Ziihera (zanidatamab-hrii) plus chemotherapy achieved a statistically significant and clinically meaningful overall survival benefit over trastuzumab plus chemotherapy in first-line treatment of HER2-positive advanced gastroesophageal adenocarcinoma (GEA), based on a second interim analysis of the Phase 3 HERIZON-GEA-01 trial.

By Editor , 3 September 2026
Defense Metals Hits 2.86% TREO Over 65m at Wicheeda Rare Earth Project

Vancouver, BC – September 03, 2026 -- Defense Metals Corp. (TSXV: DEFN; OTCQB: DFMTF; FSE:35D) reported assay results from an initial eleven core drill holes totaling 1,633 metres at its 100%-owned Wicheeda Rare Earth Project near Prince George, British Columbia, with hole WI26-96 returning 2.86% Total Rare Earth Oxide (TREO) over 65 metres, including a higher-grade interval of 6.15% TREO over 20.3 metres.

By Editor , 3 September 2026
Summit Midstream Greenlights $100M Double E Pipeline Expansion

Houston – September 03, 2026 -- Summit Midstream Corporation (NYSE: SMC) has reached a final investment decision on a mainline compression expansion for its Double E Pipeline, backed by a new 200 MMcf/d take-or-pay agreement with an investment-grade shipper that lifts total contracted firm capacity on the system to approximately 2.2 Bcf/d.

By Editor , 3 September 2026
Lilly's Taltz-Zepbound Combo Sustains Gains at 52 Weeks

INDIANAPOLIS – September 03, 2026 -- Eli Lilly and Company reported that combining Taltz (ixekizumab) with Zepbound (tirzepatide) sustained or deepened efficacy at 52 weeks in patients with psoriatic disease and obesity, building on statistically superior results already seen at Week 36 versus Taltz alone.

By Editor , 3 September 2026
Jazz's Ziihera Shows Significant Survival Edge Over Trastuzumab in GEA Trial

Dublin – September 03, 2026 -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) reported that Ziihera (zanidatamab-hrii) combined with chemotherapy produced a statistically significant and clinically meaningful overall survival (OS) benefit versus trastuzumab plus chemotherapy in a second interim analysis of the Phase 3 HERIZON-GEA-01 trial in first-line HER2-positive gastroesophageal adenocarcinoma (GEA).

By Editor , 3 September 2026

Hong Kong – September 03, 2026 -- TCL Electronics Holdings Limited (01070.HK) reported a 54.3% year-on-year surge in adjusted net profit attributable to shareholders to HK$1.64 billion for the first half of 2026, as revenue climbed 16.4% to HK$63.76 billion.

By Editor , 3 September 2026
Defense Metals Hits 2.86% TREO Over 65m at Wicheeda Rare Earth Project

VANCOUVER – September 03, 2026 -- Defense Metals Corp. (TSXV: DEFN) (OTCQB: DFMTF) (FSE:35D) has reported assay results from an initial eleven core drill holes totaling 1,633 metres at its 100%-owned Wicheeda Rare Earth Project near Prince George, British Columbia, with drill hole WI26-96 returning 2.86% Total Rare Earth Oxide (TREO) over 65 metres, including a higher-grade section averaging 6.15% TREO over 20.3 metres.

By Editor , 3 September 2026
Summit Midstream Greenlights $100M Double E Pipeline Expansion

Houston – September 03, 2026 -- Summit Midstream Corporation (NYSE: SMC) has reached a final investment decision on a mainline compression expansion for its Double E Pipeline, backed by a new 200 MMcf/d long-term firm transportation agreement with an investment-grade shipper.